Today
- Opinion
- Chanticleer
‘I want to win every time’: The Olympic-style goal driving CSL’s boss
The company’s growth forecasts for next year are a touch weaker than the market expected. But inspired by the Games, Paul McKenzie is focused on another goal.
- 26 mins ago
- James Thomson
CSL posts bumper profit but top-line growth to slow
The biotech giant says margin recovery at its core blood products business will enable it to produce double-digit earnings growth for the next half a decade.
- Michael Smith
Yesterday
- Exclusive
- Health insurance
Pressure for health premium overhaul in election headache for Albanese
The influential medical lobby is demanding an independent umpire to determine how high insurance premiums can rise as negotiations over the next increase begin.
- Michael Smith
Billionaire Salesforce boss tips into Sydney biotech incubator
Along with Marc Benioff, World Bank president Ajay Banga and Melbourne’s Churchill Asset Management all put in for a round that values the firm at $90 million.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Competition regulator delays $8.8b Chemist Warehouse deal approval
The ACCC is undertaking more analysis of the transaction, which would merge the pharmacy giant into Sigma Healthcare. A decision won’t be made until October.
- Michael Smith
This Month
Psychedelics as a serious investment? These billionaires think so
Australia is among the first countries to use the drugs for treating anxiety, depression and PTSD. A decision in the United States could be pivotal.
- Michael Smith
Pacific Smiles shares tumble as $327m buyout plan fails
Kingmaker Dr Alex Abrahams, a co-founder of dentistry group Pacific Smiles, voted his 9.5 per cent stake against the Crescent Capital offer, helping to kill it.
- Simon Evans
Switzerland’s Unilabs takes a look at $4b I-MED radiology business
The company’s British private equity owners, Permira, brought in Morgan Stanley and Jefferies earlier this year to work on plans for a bumper payday.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Pfizer invests $150m in Melbourne to fight superbugs
The US pharma giant says the federal government must do more to ensure Australians can access new drugs designed to fight deadly superbugs.
- Michael Smith
Ramsay tips lower earnings, hospital capex weak
Ramsay Health Care says full-year earnings will be weaker than expected as it flags writedowns on its European operations.
- Michael Smith
- Exclusive
- Healthcare
Hospitals seek right to boycott big insurers from funding talks
Catholic-operated private hospitals want a major shake-up of the way they negotiate funding deals with health insurers, in an escalation of tensions between the two sides.
- Michael Smith
Entrepreneur returns with buyout after five-year non-compete clause
Craig Silbery funded his first business on a credit card and 12 years later sold it for $690 million to a Chinese giant. He aims to repeat the growth with a probiotics business acquired after a forced five years out of the industry.
- Simon Evans
ResMed says sales growth defies weight-loss fears
Chief executive Mick Farrell says he is confident the company has put to bed investor fears that weight-loss drugs will hurt sales of its sleep apnoea products.
- Michael Smith
High cholesterol critical factor in development of dementia, study finds
Scientists have for the first time linked high cholesterol and vision loss to the onset of dementia, including them among 14 risk factors.
- Sarah Neville
Genesis remains defiant on blocking Crescent’s Pacific Smiles bid
Street Talk understands Genesis Capital isn’t done yet and will continue to use its considerable stake to thwart the bid.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Crescent Capital returns with $327m bid for Pacific Smiles
The battle between private equity players Genesis and Crescent took another twist, with the owner of the National Dental Care network lifting its offer.
- Simon Evans
Crescent set to come back with knockout bid for Pacific Smiles
Street Talk understands Michael Alscher has come back fighting overnight, expected to increase the firm’s bid north of $2 per share.
- Sarah Thompson, Kanika Sood and Emma Rapaport
July
- Opinion
- Chanticleer
The PE takeover battle that is like pulling teeth
Once a board has decided a takeover isn’t about the highest price, it enters the deal-making twilight zone. This one is a doozy.
- Anthony Macdonald
Pacific Smiles board says lower private equity offer is better
A shareholder vote on a $305m buyout has been postponed, with the onus back on Crescent Capital to make a counter-proposal for the dentistry group.
- Simon Evans
- Investigation
- Cyprus Confidential
Importers got rich on COVID masks; the shipment’s still on the dock
When COVID-19 erupted around the world, the race was on to secure masks and gowns. Middlemen were in lucrative taxpayer deals, even one which went awry.
- Liam Walsh and Neil Chenoweth
